A Randomized Clinical Trial Comparing Methotrexate and Mycophenolate Mofetil for Noninfectious Uveitis-Reference-Cited by-同舟云学术

A Randomized Clinical Trial Comparing Methotrexate and Mycophenolate Mofetil for Noninfectious Uveitis

Published:2014-10 Issue:10 Volume:121 Page:1863-1870
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Rathinam Sivakumar R.,Babu Manohar,Thundikandy Radhika,Kanakath Anuradha,Nardone Natalie,Esterberg Elizabeth,Lee Salena M.,Enanoria Wayne T.A.,Porco Travis C.,Browne Erica N.,Weinrib Rachel,Acharya Nisha R.

Publisher

Elsevier BV

Subject

Ophthalmology

Reference30 articles.

1. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel;Jabs;Am J Ophthalmol,2000

2. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation;Galor;Ophthalmology,2008

3. Emerging drugs for uveitis;Larson;Expert Opin Emerg Drugs,2011

4. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients;Siepmann;Graefes Arch Clin Exp Ophthalmol,2006

5. Mycophenolate mofetil for the treatment of uveitis;Teoh;Am J Ophthalmol,2008

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes in Patients With Vogt–Koyanagi–Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial;American Journal of Ophthalmology;2024-11

2. Use of immunomodulators in non-infectious uveitis: lights and shadows;Eye;2024-08-19

3. Can Simvastatin Reduce the Need for Immunomodulatory Drugs to Treat Uveitis?;Ophthalmology Science;2023-12

4. Healthcare professionals’ views on the most important outcomes for non-infectious uveitis of the posterior segment: A qualitative study;PLOS ONE;2023-11-17

5. Trends in Immunosuppressive Agent Use for Non-Infectious Uveitis by US Ophthalmologists in Medicare Beneficiaries and Association with Physician–Industry Interactions;Ocular Immunology and Inflammation;2023-11-02